ArticleIBRO neuroscience reports2026
Mechanisms of electroacupuncture for the treatment of Alzheimer's disease by activating Wnt/β-catenin pathway to improve blood-brain barrier function.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: In this study, we used APP/PS1 mice as a research vehicle to illustrate that electroacupuncture can improve the blood-brain barrier function by activating the Wnt/β-catenin pathway for the treatment of Alzheimer's disease (AD). Methods: 18 7-month-old SPF APP/PS1 male double-transgenic mice were selected as AD model mice and randomly divided into model group, electroacupuncture group and donepezil hydrochloride group, with 6 mice in each group, and 6 C57BL/6 J male mice as normal group. After the end of the intervention, the mice in each group were subjected to Morris water maze behavioural test. After the behavioural test, the pathological morphology of hippocampal tissue was observed by HE staining method, Aβ was detected in the hippocampal region of mice by IHC method, the mRNA expression of Axin2 and Dkk1 was detected in hippocampal tissue by Real-time PCR method, and the tight junction protein, Claudin-5, was detected in hippocampal region of mice by Western Blot method. Claudin-5, Occludin protein with active β-catenin, p-GSK3β protein expression in mouse hippocampus by Western Blot. Results: EA can improve the learning ability of APP/PS1 mice, restore the morphology and structure of the hippocampus, reduce the positive expression of Aβ in the hippocampus, down-regulate the expression of Axin2 and Dkk1 mRNA, and elevate the expression of the tight junction-related proteins, Claudin-5, Occludin with active β-catenin, and p-GSK3β. Conclusion: EA can improve the expression of blood-brain barrier-related molecules in AD mice by regulating the expression of molecules related to the Wnt/β-catenin pathway, which is beneficial to the early treatment of AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.